Teva Pharmaceutical Industries (TEVA) closed at $44.50 on November 13, 2026, up 1.9% from the previous close, on volume of 6,210,800 shares (30-day average 6,946,006).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | Calendar Call Ladder | 18-Dec-2642 C|15-Jan-2744 : 49 C | 6,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Mon, 16-Nov 8:00 AM ET)
Teva (TEVA) Receives a Buy from TD Cowen
TipRanks (Fri, 13-Nov 6:05 AM ET)
Teva’s Innovation-Led Pipeline and Expanding Portfolio Support a $54 Price Target
TipRanks (Fri, 13-Nov 1:25 AM ET)
Evercore ISI Keeps Their Buy Rating on Teva (TEVA)
TipRanks (Thu, 12-Nov 5:15 PM ET)
Oppenheimer Sticks to Its Buy Rating for Teva (TEVA)
TipRanks (Thu, 12-Nov 12:45 PM ET)
Bank of America Securities Remains a Buy on Teva (TEVA)
TipRanks (Thu, 12-Nov 9:45 AM ET)
Teva outlines 2030 targets ahead of R&D Day event
Seeking Alpha News (Wed, 11-Nov 8:15 AM ET)
Globe Newswire (Wed, 11-Nov 7:30 AM ET)
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Globe Newswire (Tue, 3-Nov 5:00 AM ET)
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Industries trades on the NYSE stock market under the symbol TEVA.
As of November 16, 2026, TEVA stock price declined to $43.67 with 1,431,099 million shares trading.
TEVA has a beta of 1.09, meaning it tends to be more sensitive to market movements. TEVA has a correlation of 0.15 to the broad based SPY ETF.
TEVA has a market cap of $50.93 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries reported $4 billion in Revenue and $.86 earnings per share. This beat revenue expectation by $146 million and exceeded earnings estimates by $.14.
In the last 3 years, TEVA traded as high as $44.57 and as low as $8.64.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): IEFA, EFA, EIS, IXUS, EFG.
TEVA has outperformed the market in the last year with a price return of +71.0% while the SPY ETF gained +12.1%. TEVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.6% and +3.8%, respectively, while the SPY returned -3.9% and -1.3%, respectively.
TEVA support price is $43.65 and resistance is $45.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA shares will trade within this expected range on the day.